Literature DB >> 9676913

Topical modulation of interleukin-1 activity in corneal neovascularization.

M R Dana1, S N Zhu, J Yamada.   

Abstract

PURPOSE: To determine whether inflammatory corneal neovascularization (CNV) is associated with interleukin-1 (IL-1) activity and if so, to assess the efficacy of topical interleukin-1 receptor antagonist (IL-1ra) to suppress CNV.
METHODS: Inflammatory CNV was induced on day 0 by placement of paracentral intrastromal sutures in BALB/c murine eyes. Quantification of IL-1alpha and -beta cytokine levels was done by a sandwich enzyme-linked immunosorbent assay (ELISA) on the supernatants of incubated corneas excised at specified time points after induction of CNV (n = 6 per time point studied). To study suppression of CNV by IL-1ra, animals were divided into treatment subgroups that received topical 20 mg/ml of IL-1ra mixed in 0.2% sodium hyaluronate (n = 28) or placebo (vehicle) alone (n = 22) 3 times daily during days 0-35. Other groups of animals received placebo for 1 (n = 10) or 2 (n = 14) weeks before being switched and retained on IL-1ra. Neovascularization was assessed biomicroscopically and graded by using a standardized scheme.
RESULTS: Induction of CNV stimulus was associated with a significant surge in the expression of both IL-1alpha (p < 0.001) and IL-1beta (p < 0.001) as early as 2 h after the stimulus, which peaked at 24 h, before decreasing substantially in the case of IL-1beta and returning to basal levels by day 7. Topical application of IL-1ra led to a significant suppression of CNV for the duration of therapy only if initiated early after induction of the neovascular stimulus. Initiation of therapy 1 week after CNV induction was associated only with a transient suppression in the angiogenic response.
CONCLUSION: Our data strongly implicate IL-1 as a critical mediator in the early phase of CNV and suggest that IL-1ra can be an effective modality in suppressing CNV if initiated sufficiently early after the inflammatory neovascular stimulus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9676913     DOI: 10.1097/00003226-199807000-00011

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  43 in total

1.  Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma.

Authors:  Pierre L Triozzi; Wayne Aldrich; Arun Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-25       Impact factor: 4.799

2.  Suppression of transcription factor early growth response 1 reduces herpes simplex virus 1-induced corneal disease in mice.

Authors:  Hui-Wen Yao; Shih-Heng Chen; Ching Li; Yuk-Ying Tung; Shun-Hua Chen
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

3.  Innate recognition network driving herpes simplex virus-induced corneal immunopathology: role of the toll pathway in early inflammatory events in stromal keratitis.

Authors:  Pranita P Sarangi; Bumseok Kim; Evelyn Kurt-Jones; Barry T Rouse
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

4.  Role of miR-155 in the pathogenesis of herpetic stromal keratitis.

Authors:  Siddheshvar Bhela; Sachin Mulik; Fernanda Gimenez; Pradeep B J Reddy; Raphael L Richardson; Siva Karthik Varanasi; Ujjaldeep Jaggi; John Xu; Patrick Y Lu; Barry T Rouse
Journal:  Am J Pathol       Date:  2015-02-18       Impact factor: 4.307

Review 5.  Clinical correlates of common corneal neovascular diseases: a literature review.

Authors:  Nizar Saleh Abdelfattah; Mohamed Amgad; Amira A Zayed; Hamdy Salem; Ahmed E Elkhanany; Heba Hussein; Nawal Abd El-Baky
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

6.  Corneal epithelial proliferation and thickness in a mouse model of dry eye.

Authors:  Claudia Fabiani; Stefano Barabino; Saadia Rashid; M Reza Dana
Journal:  Exp Eye Res       Date:  2009-03-17       Impact factor: 3.467

Review 7.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

8.  Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival.

Authors:  Parisa Emami-Naeini; Thomas H Dohlman; Masahiro Omoto; Takaaki Hattori; Yihe Chen; Hyun Soo Lee; Sunil K Chauhan; Reza Dana
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-05       Impact factor: 3.117

9.  Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization.

Authors:  Peng Chen; Hongmei Yin; Yao Wang; Jing Mi; Wenxiao He; Lixin Xie; Yiqiang Wang
Journal:  Mol Vis       Date:  2010-02-27       Impact factor: 2.367

10.  S100A proteins in the pathogenesis of experimental corneal neovascularization.

Authors:  Changyou Li; Feng Zhang; Yiqiang Wang
Journal:  Mol Vis       Date:  2010-10-31       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.